Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a ...

In what is being hailed as a “groundbreaking achievement” for Uruguay and South America, a weight loss drug has successfully ...

Viking Therapeutics VKTX reported second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

The biologic and biosimilar era has brought about more clinical trials in rheumatology than ever before, and with increasing ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...